SETH LERNER to Pyridines
This is a "connection" page, showing publications SETH LERNER has written about Pyridines.
Connection Strength
0.253
-
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20; 42(33):3911-3916.
Score: 0.203
-
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU Int. 2024 10; 134(4):596-601.
Score: 0.050